Hyplaxy

Hydroxychloroquine sulfate, the active ingredient in Hyplaxy, is an antimalarial and disease-modifying antirheumatic drug (DMARD) presented as an oral dosage form for systemic use. It is employed in the prevention and treatment of malaria and in managing autoimmune conditions such as rheumatoid arthritis and systemic lupus erythematosus.

GNH USA supplies Hyplaxy as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory documentation and logistics support for global healthcare providers through established distribution networks and quality‑assured manufacturing.

Hydroxychloroquine sulfate is used in antimalarial therapy and as an immunomodulator for certain autoimmune diseases.

- Malaria prophylaxis and treatment: Prevents infection and treats acute episodes of Plasmodium malaria. - Rheumatoid arthritis: Reduces joint inflammation and slows disease progression. - Systemic lupus erythematosus: Controls disease activity and decreases flare frequency.

Hydroxychloroquine sulfate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose stools. - Headache: transient cranial pain. - Skin rash: mild erythema or itching.

Serious or Rare Side Effects: - Retinal toxicity: irreversible vision loss requiring ophthalmologic monitoring. - Cardiac arrhythmia: QT prolongation or cardiomyopathy. - Severe hypoglycemia: especially in diabetic patients. - Hemolysis in G6PD deficiency: risk of red blood cell destruction.

When prescribing hydroxychloroquine, clinicians should consider several safety measures.

- Baseline ophthalmologic exam: obtain eye exam before therapy and annually thereafter. - Renal or hepatic impairment: adjust monitoring and consider dose modification. - Concomitant QT‑prolonging drugs: avoid or monitor cardiac rhythm closely. - Pregnancy and lactation: use only if benefit outweighs potential risk. - G6PD deficiency: screen patients to prevent hemolytic anemia. - Store at below 25°C: keep in original packaging, protect from moisture and direct sunlight.

Hydroxychloroquine has notable drug interaction potential that requires attention.

Major Interactions (Avoid): - Antacids containing aluminum or magnesium: reduce absorption of hydroxychloroquine. - Strong CYP450 inhibitors (e.g., ketoconazole): increase plasma concentrations, risk of toxicity. - QT‑prolonging agents (e.g., quinidine, amiodarone): may cause serious cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Digoxin: hydroxychloroquine may increase serum levels. - Insulin or oral hypoglycemics: enhanced hypoglycemic effect. - Cyclosporine: may increase risk of retinal toxicity. - Azithromycin: additive QT prolongation risk.